Bolden Therapeutics Awarded Small Business Technology Transfer Grant

Last month, Brown startup, Bolden, was awarded a Small Business Technology Transfer (SBTT) grant of $500,000 from the National Institute on Aging for their approach to enhance neurogenesis. Bolden Therapeutics is a biotechnology company that develops therapeutics to promote neurogenesis in patients with diseases that affect cognition, such as Alzheimer’s.

Bolden has licensed several patents produced from Brown University faculty inventors. The projects funded by the SBTT grant will be completed in collaboration with the labs of Justin Fallon, PhD (Molecular Biology, Cell Biology & Biochemistry, MCB) and Ashley Webb, PhD (MCB). The work of Fallon and Webb has identified molecular pathways whose activity stimulates neurogenesis. Bolden plans to develop therapeutics that could promote neurogenesis and improve memory in Alzheimer’s patients. Learn About the Award.